Summary.-The hypoxic cell sensitizer Misonidazole (Ro-07-0582) induces oncogenic transformations in the C3H/1OTI mouse embryo cell line cultured in vitro. A drug concentration of 04 mM applied to aerated cells for 3 or 6 days results in a transformation rate comparable to that observed following an X-ray dose of 1 Gray. A higher drug concentration of 6 0 mM is equivalent to 4 Gy. The combination of Misonidazole and X-rays produces a significant increase in the frequency of transformation over either drug or radiation alone, but the data are equivocal on the question of additivity vs synergism.
CELLS DEFICIENT in oxygen are relatively resistant to killing by X-or y-rays, and it has frequently been suggested that this fact limits the radiocurability of some human tumours by conventional radiotherapy. In recent years, a variety of compounds have been studied which selectively sensitize hypoxic mammalian cells to X-or y-rays. The most promising of the new drugs is the 2-nitroimidazole, Misonidazole (Ro-07-0582), which satisfies many of the criteria essential for a clinically useful sensitizer (Adams, 1973; Adams and Dewey, 1963; Asquith et al., 1974) . Following extensive investigations with radiobiological test systems in vitro and in vivo, Misonidazole (MIS) is currently undergoing clinical trials in humans (Brown, 1975; Chapman et al., 1973; Denekamp and Harris, 1975; Foster et al., 1976; Gray et al., 1976; Hall and RoizinTowle, 1975) . From Speck et al. (1976) and Voogd et al. (1974) , who established that the family of 5-nitroimidazole derivatives have mutagenic potential in two strains of bacteria, K. pneumoniae and S. typhimuritm. With the increased probability of long-term patient survival after the combination of radiation and the new sensitizers, it is important to consider possible late effects. Specifically, the carcinogenicity of MIS must be determined in order to allow an assessment of the risks and benefits involved in using the nitroimidazoles as adjuncts to radiotherapy.
MATERIALS AND METHODS
(a) Culture of the cells.-The C3H/1OT1 cell line, developed in the laboratory of Charles Heidelberger, has been reported to be highly sensitive to post-confluence inhibition of cell division (Reznikoff et al., 1973a) . These cells are fibroblasts from the ventral prostate of C3H mouse embryos. Cells used for experiments were between Passages 12 and 16, because of the report that cells of later passages have an incidence of spontaneous transformation. Cells were grown in Eagle's basal medium (BME), supplemented with 10% heat-inactivated foetal calf serum. Penicillin (50 u/ml) and streptomycin (50 jug/ml) were added to control bacterial contamination. Cells were seeded into 100 mm Falcon plastic Petri dishes 24 h before the treatment with MIS or X-rays or both; the number of cells plated was such that between 350 and 450 viable cells per dish survived the subsequent treatment. A range of drug concentration was used, and the cells were treated for 3 days or 6 days. At the termination of the drug exposure, medium containing MIS was replaced with fresh drug-free complete medium. Subsequently, medium was changed weekly for 6 weeks until untransformed cells had formed a confluent layer in the dish, and transformed foci were large enough to be readily visible.
(b) Transformation evaluation.-Transformed foci were evaluated using the morphological criteria described by Reznikoff et al. (1973a, b (Fig. 1) . Only Type 3 foci were scored as transformants since Reznikoff et al. (1973b) Fig. 3 , where the fraction of cells surviving is plotted against the drug concentration for a 3-or 6-day exposure. Inhibition of the growth of V79 cells under aerated conditions while exposed to high concentrations of MIS was previously reported by Stratford and Adams (1977 A series of experiments was performed in which concentrations of MIS from 0.4 to 8 mm were added to cells for either 3 or 6 days, and the rate of transformation subsequently assayed. The data are summarized in Table I and plotted in Fig. 4b , where the number of transformants per surviving cell is plotted as a function of drug concentration. A total of 27 separate experiments were performed, most of them involving the clinically relevant drug concentrations in the range 0 4 to 2 mm.
The lowest concentration used (0.4 mM) resulted in a significant transformation rate. In experiments performed at this laboratory during the past year a total of over one million clones have been counted on the control dishes (without drug) without the appearance of a single transformed clone. This means that the spontaneous Fig. 4a shows the relationship between transformation and X-ray dose; the number of transformants per surviving cell increases with dose, but approaches a plateau at a frequency of about 2 x 10-3 for doses over 6 Gy. By comparing Panels (a) and (b) of Fig. 4 it is possible to calculate the drug concentrations that are equivalent to various doses of X-rays in their ability to induce transformation. This "equivalence" is summarized in Fig. 5 , where the dose of radiation is plotted against the concentration of MIS which results in the same frequency of transformation. The results of experiments in which MIS was combined with X-rays are summarized in Table II and plotted in Fig. 6 . The combination of drug and radiation resulted in a significant increase in the frequency of transformations compared with X-rays or drug alone. The drug treatment was a 3-day exposure to a concentration of 1 mm, beginning 24 h before irradiation and continuing for 48 h afterwards. Three doses of X-rays were used, 1, 2 and 4 Gy. addition to the armamentarium of the radiotherapist because it sensitizes hypoxic cells which are otherwise relatively resistant to X-rays and may limit the radiocurability of some human tumours (Asquith et al., 1974; Denekamp and Harris, 1975; Thomlinson and Gray, 1955) . MIS may also find a place in multidrug chemotherapy regimens, because it, is also cytotoxic towards hypoxic cells (Hall et al., 1977, Hall and Roizin-Towle, 1975; Stratford and Adams, 1977) . These undoubted benefits must be weighed against the possibility that the nitroimidazoles are potent carcinogens.
When MIS is used clinically as a sensitizer in conjunction with radiotherapy, serum levels in the range 0 5 to 1 mm can be achieved. The maximum serum concentration occurs 3 to 4 h after oral administrations of the drug, and subsequently decays exponentially with a half-life of ,-1,2 h. Based on Fig. 5 , this drug treatment carried with it a carcinogenic potential equal to an X-ray dose of about 1 Gy. It is pertinent to note that when radiation is used as a therapeutic modality, the high dose is confined to the tumour, its immediate surroundings and the necessary transit normal tissues. By contrast, when MIS is used clinicallv it comes into contact with virtually all the normal tissues of the body.
The experiments combining MIS and X-rays showed that the combination produces a significant increase in the frequency of transformations compared with either the drug or the radiation alone. It wrould clearly be of interest to know whether the interaction between the two agents is additive or synergistic. The drug treatment alone (1 mm for 3 days) resulted in a transformation frequency of about 2*5X 10-4. A dose of 1 Gy alone produced a transformation frequency of about 2 1 x 10-4. The combination of 1 Gy plus drug resulted in a frequency of about 5-2 x 10-4, which is not significantly different from the sum of the individual contributions of the two modalities (2.5+2.1=z46) which would suggest additivity between radiation and drug. However, when 2 Gy of X-rays was combined with the drug treatment, the transformation frequency produced (13 x 10-3) was significantly greater than the sum of the frequencies produced by drug and radiation alone (2-5+3*2= 5.7 X 10-4) which suggests synergism in the action of drug and radiation. It is difficult to draw any conclusions from the highest radiation dose used, because the transformation frequency produced by 4 Gy+ drug approaches the plateau of about 2 x 10-3, which appears never to be exceeded by either radiation or drug treatments. The present data, therefore, clearly show that combining radiation and MIS results in more transformations than either agent alone, but is equivocal on the question of additivity vs synergism.
These studies with an in vitro transformation system have shown that the new generation of hypoxic cell sensitizers have as great a potential as radiation for producing oncogenic transformation. They highlight the need for further investigations with more complex animal model systems. When new drugs such as MIS have passed their early clinical tests and are used in younger patients with less advanced tumours, who therefore have a longer life expectancy, the possibility of inducing a second neoplasm while treating the first can no longer be ignored. This investigation was supported by Contract EP-78-S-02-4733 from the Department of Energy and Grants Number CA-12536 and CA-18506 awarded by the National Cancer Institute, DHEW. The drug Misonidazole was generously supplied by the Roche Company, and we gladly acknowledge much fruitful discussion with Professor G. E. Adams n the design of this investigation.
